Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer
Portfolio Pulse from Vandana Singh
Gilead Sciences Inc (NASDAQ:GILD) announced that its Phase 3 TROPiCS-04 study for Trodelvy in treating metastatic urothelial cancer did not meet its primary endpoint of overall survival. The study showed numerical improvement in overall survival favoring Trodelvy, but also a higher number of deaths due to adverse events compared to chemotherapy. Gilead will further investigate the data and discuss next steps with the FDA. GILD shares were trading lower by 2.23% premarket.
May 31, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gilead Sciences' Phase 3 TROPiCS-04 study for Trodelvy in metastatic urothelial cancer did not meet its primary endpoint of overall survival. The study showed a numerical improvement in overall survival favoring Trodelvy but also a higher number of deaths due to adverse events compared to chemotherapy. Gilead will further investigate the data and discuss next steps with the FDA. GILD shares were trading lower by 2.23% premarket.
The failure to meet the primary endpoint in a late-stage study is a significant setback for Gilead, especially given the higher number of deaths due to adverse events. This news is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100